Skip to main content
Back to Kleiner Perkins

Kleiner Perkins's Therapeutics Portfolio

Browse 7 Therapeutics companies funded by Kleiner Perkins. See funding amounts, founder contacts, and investment details.

Therapeutics Companies
7
Total Funding in Therapeutics
$429.0M

Therapeutics Portfolio Companies (7)

Export
BiotechnologyHealth CareOncologyTherapeutics

Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.

South San Francisco, United States
May 2026
$550K
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

Clinical TrialsHealth CareMedical DeviceTherapeutics

Developed the first FDA-cleared digital therapeutic that significantly reduces/eliminates symptoms of panic attacks & PTSD in only 28 days

Kirkland, United States
April 2024
$22.6M
Series E

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareTherapeutics

Expansion Therapeutics is a biotechnology company focusing on developing transformative oral medicines for severe RNA-mediated diseases.

San Diego, United States
January 2023
$6.9M
Venture - Series Unknown

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

South San Francisco, United States
October 2025
$250.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

Health CareMental HealthmHealthSoftwareTherapeuticsWellness

Modern Health is a mental well-being platform for companies offering therapy, coaching, and self-guided courses.

San Francisco, United States
February 2021
$74.0M
Series D

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareTherapeutics

Cell Design Labs is a biotherapeutics company

San Francisco, United States
January 2021
Private Equity

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsHealth CareManufacturingTherapeutics

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells.

Philadelphia, United States
October 2019
$75.0M
Series B

Founder Contacts

30,000+ verified contacts

Explore Kleiner Perkins's Full Portfolio

View all companies funded by Kleiner Perkins across every industry and funding stage.

View Full Kleiner Perkins Portfolio